Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06568042 | Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy | PHASE2 | ACTIVE NOT_RECRUITING | 558 | — | — | Aug 22, 2024 | Sep 1, 2026 | Apr 29, 2026 | 76 | United States, Canada +5 |
| Arm | Type | Description |
|---|---|---|
| LY3848575 Dose 1 | EXPERIMENTAL | LY3848575 low dose administered subcutaneously (SC). |
| LY3848575 Dose 2 | EXPERIMENTAL | LY3848575 mid dose administered SC. |
| LY3848575 Dose 3 | EXPERIMENTAL | LY3848575 high dose administered SC. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3848575 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a Visual Analog Scale (VAS) pain value ≥40 and \<95 at screening. * Presence of painful distal sensory polyneuropathy (DSP) without prominent motor or autonomic features with gradual or insidious onset with a minimum duration of 6 months and a known cause of nerve injury,...